Clementia Pharmaceuticals (Clementia Pharmaceuticals) Net Change in Cash : $-17.04 Mil (TTM As of Dec. 2018)

View and export this data going back to 2017. Start your Free Trial

What is Clementia Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Clementia Pharmaceuticals's Net Change in Cash for the three months ended in Dec. 2018 was $7.13 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2018 was $-17.04 Mil.

Clementia Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Clementia Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clementia Pharmaceuticals Net Change in Cash Chart

Clementia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Net Change in Cash

2.09

52.60

-48.67

26.80

58.74

Clementia Pharmaceuticals Quarterly Data
	Dec14	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Net Change in Cash	Get a 7-Day Free Trial									-1.01	-9.59	-13.70	-0.88	7.13

Clementia Pharmaceuticals Net Change in Cash Calculation

Clementia Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2018 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-49.145	+	32.228	+	75.782	+	-0.123
	=	58.74

Clementia Pharmaceuticals's Net Change in Cash for the quarter that ended in Dec. 2018

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -12.996 + 20.212 + 0 + -0.082

= 7.13

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clementia Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Clementia Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clementia Pharmaceuticals Inc (NAS:CMTA) » Definitions » Net Change in Cash

Comparable Companies

RETA HKSE:01061 XKRX:144510 XKRX:083790 ACRS NCNA PGNX CDXS OSTO:CAMX ASX:MSB CASC GLYC ACHN XKRX:048530 TSX:TH ROCO:4157 LSE:OXB XKRX:141080 CNCE AGEN

Traded in Other Exchanges

N/A

Address

4150 St Catherine Street West, Suite 550, Montreal, QC, CAN, H3Z 2Y5

Website

http://www.clementiapharma.com

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). It believes that if approved in FOP or MO, palovarotene could become the standard of care in either or both of these indications.

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Headlines

From GuruFocus

Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
By Marketwired Marketwired • 05-23-2018

Clementia Announces Pricing of Public Offering of Common Shares
By GlobeNewswire GlobeNewswire • 10-30-2018

SHAREHOLDER ALERT: WeissLaw LLP Investigates Clementia Pharmaceuticals, Inc.
By PRNewswire PRNewswire • 03-01-2019

Recent Analysis Shows Clementia Pharmaceuticals, Superior Group of Companies, ACM Research, Atlantic Capital Bancshares, Customers, and GW Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
By Marketwired Marketwired • 06-06-2018

Clementia Announces Proposed Public Offering of Common Shares
By Marketwired Marketwired • 10-30-2018

Clementia Announces Cancellation of Fourth Quarter and Year-End 2018 Financial Results and Conference Call
By Marketwired Marketwired • 02-26-2019

Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference
By Marketwired Marketwired • 02-20-2019

Clementia Announces Pricing of Public Offering of Common Shares
By Marketwired Marketwired • 10-30-2018

MERGER ALERT – CMTA and ONCE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
By Marketwired Marketwired • 03-26-2019

Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
By Marketwired Marketwired • 10-02-2018